Email This Article
Questions Arise as Genta Expands Cancer Drug Trial
By
Adam Feuerstein
04/04/02 - 04:29 PM EST
The company is adding patients to its nonblinded study of melanoma drug Genasense.
The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,309.92 | 1,091.49 | 2,138.44 | 32.31 |
Oil *
77.12
|
|
DOWN
154.48
|
DOWN
19.14
|
DOWN
37.61
|
DOWN
0.48
|
10 Yr
3.23%
SPDR Gold
115.06
|
|
-1.48%
|
-1.72%
|
-1.73%
|
-1.46%
|
Data delayed 20 minutes |


Connect with TheStreet